Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage

I-Chin Wu; Ching-Lung Lai; Steven-Huy Han; Kwang-Hyup Han; Stuart Gordon; You-Chen Chao; Chee-Kiat Tan; William Sievert; Tawesak Tanwandee; Dong Xu; Boon-Leong Neo; Ting-Tsung Chang

doi:10.1002/hep.23424

Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage

I-Chin Wu, Ching-Lung Lai, Steven-Huy Han, Kwang-Hyup Han, Stuart Gordon, You-Chen Chao, Chee-Kiat Tan, William Sievert, Tawesak Tanwandee, Dong Xu, Boon-Leong Neo, Ting-Tsung Chang

Medicine Monash Health

Research output: Contribution to journal › Article › Research › peer-review

43 Citations (Scopus)

Abstract

Current guidelines for management of chronic hepatitis B recommend treatment for patients presenting with elevated hepatitis B virus (HBV) DNA and alanine aminotransferase (ALT) >2 x upper limit of normal (ULN) or histological evidence of liver disease. Retrospective analyses have demonstrated that significant hepatic necroinflammation and fibrosis were present in a substantial proportion of patients with ALT 1 to 2 x ULN. To assess therapeutic efficacy in this clinical setting, we retrospectively examined treatment endpoints among the subset of nucleoside-na??ve chronic hepatitis B (CHB) patients treated in phase 3 clinical trials of entecavir who had both screening and baseline serum ALT 1.3 to 2 x ULN. A total of 1347 patients were randomized to treatment with entecavir or lamivudine.

Original language	English
Pages (from-to)	1185 - 1189
Number of pages	5
Journal	Hepatology
Volume	51
Issue number	4
DOIs	https://doi.org/10.1002/hep.23424
Publication status	Published - 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/hep.23424

Cite this

Wu, I-Chin ; Lai, Ching-Lung ; Han, Steven-Huy ; Han, Kwang-Hyup ; Gordon, Stuart ; Chao, You-Chen ; Tan, Chee-Kiat ; Sievert, William ; Tanwandee, Tawesak ; Xu, Dong ; Neo, Boon-Leong ; Chang, Ting-Tsung. / Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. In: Hepatology. 2010 ; Vol. 51, No. 4. pp. 1185 - 1189.

@article{2d77d29379ce4e39b7411f136864e876,

title = "Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage",

abstract = "Current guidelines for management of chronic hepatitis B recommend treatment for patients presenting with elevated hepatitis B virus (HBV) DNA and alanine aminotransferase (ALT) >2 x upper limit of normal (ULN) or histological evidence of liver disease. Retrospective analyses have demonstrated that significant hepatic necroinflammation and fibrosis were present in a substantial proportion of patients with ALT 1 to 2 x ULN. To assess therapeutic efficacy in this clinical setting, we retrospectively examined treatment endpoints among the subset of nucleoside-na??ve chronic hepatitis B (CHB) patients treated in phase 3 clinical trials of entecavir who had both screening and baseline serum ALT 1.3 to 2 x ULN. A total of 1347 patients were randomized to treatment with entecavir or lamivudine.",

author = "I-Chin Wu and Ching-Lung Lai and Steven-Huy Han and Kwang-Hyup Han and Stuart Gordon and You-Chen Chao and Chee-Kiat Tan and William Sievert and Tawesak Tanwandee and Dong Xu and Boon-Leong Neo and Ting-Tsung Chang",

year = "2010",

doi = "10.1002/hep.23424",

language = "English",

volume = "51",

pages = "1185 -- 1189",

journal = "Hepatology",

issn = "0270-9139",

publisher = "John Wiley & Sons",

number = "4",

}

Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. / Wu, I-Chin; Lai, Ching-Lung; Han, Steven-Huy; Han, Kwang-Hyup; Gordon, Stuart; Chao, You-Chen; Tan, Chee-Kiat; Sievert, William; Tanwandee, Tawesak; Xu, Dong; Neo, Boon-Leong; Chang, Ting-Tsung.

In: Hepatology, Vol. 51, No. 4, 2010, p. 1185 - 1189.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage

AU - Wu, I-Chin

AU - Lai, Ching-Lung

AU - Han, Steven-Huy

AU - Han, Kwang-Hyup

AU - Gordon, Stuart

AU - Chao, You-Chen

AU - Tan, Chee-Kiat

AU - Sievert, William

AU - Tanwandee, Tawesak

AU - Xu, Dong

AU - Neo, Boon-Leong

AU - Chang, Ting-Tsung

PY - 2010

Y1 - 2010

N2 - Current guidelines for management of chronic hepatitis B recommend treatment for patients presenting with elevated hepatitis B virus (HBV) DNA and alanine aminotransferase (ALT) >2 x upper limit of normal (ULN) or histological evidence of liver disease. Retrospective analyses have demonstrated that significant hepatic necroinflammation and fibrosis were present in a substantial proportion of patients with ALT 1 to 2 x ULN. To assess therapeutic efficacy in this clinical setting, we retrospectively examined treatment endpoints among the subset of nucleoside-na??ve chronic hepatitis B (CHB) patients treated in phase 3 clinical trials of entecavir who had both screening and baseline serum ALT 1.3 to 2 x ULN. A total of 1347 patients were randomized to treatment with entecavir or lamivudine.

AB - Current guidelines for management of chronic hepatitis B recommend treatment for patients presenting with elevated hepatitis B virus (HBV) DNA and alanine aminotransferase (ALT) >2 x upper limit of normal (ULN) or histological evidence of liver disease. Retrospective analyses have demonstrated that significant hepatic necroinflammation and fibrosis were present in a substantial proportion of patients with ALT 1 to 2 x ULN. To assess therapeutic efficacy in this clinical setting, we retrospectively examined treatment endpoints among the subset of nucleoside-na??ve chronic hepatitis B (CHB) patients treated in phase 3 clinical trials of entecavir who had both screening and baseline serum ALT 1.3 to 2 x ULN. A total of 1347 patients were randomized to treatment with entecavir or lamivudine.

UR - http://onlinelibrary.wiley.com/doi/10.1002/hep.23424/pdf

U2 - 10.1002/hep.23424

DO - 10.1002/hep.23424

M3 - Article

VL - 51

SP - 1185

EP - 1189

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 4

ER -

Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage

Abstract

UN SDGs

Access to Document

Other files and links

Cite this